Darolutamide in Metastatic Prostate Cancer

Affiliations

¹ Uniformed Services University of the Health Sciences, Bethesda, MD gartrell.bowling@usuhs.edu.
² Food and Drug Administration, Silver Spring, MD.

Comment

Gartrell C Bowling et al. N Engl J Med. 2022.

. 2022 Jun 16;386(24):2344.

doi: 10.1056/NEJMc2205310.

¹ Uniformed Services University of the Health Sciences, Bethesda, MD gartrell.bowling@usuhs.edu.
² Food and Drug Administration, Silver Spring, MD.

No abstract available

Comment in

Darolutamide in Metastatic Prostate Cancer. Reply.
Smith MR. Smith MR. N Engl J Med. 2022 Jun 16;386(24):2345. doi: 10.1056/NEJMc2205310. N Engl J Med. 2022. PMID: 35704494 No abstract available.

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.